BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mc Mahon A, Martin-Loeches I. The pharmacological management of severe influenza infection - 'existing and emerging therapies'. Expert Rev Clin Pharmacol 2017;10:81-95. [PMID: 27797595 DOI: 10.1080/17512433.2017.1255550] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Wasik MA, Eichwald L, Genzel Y, Reichl U. Cell culture-based production of defective interfering particles for influenza antiviral therapy. Appl Microbiol Biotechnol 2018;102:1167-77. [PMID: 29204901 DOI: 10.1007/s00253-017-8660-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
2 Yu Y, Zhang Y, Wang S, Liu W, Hao C, Wang W. Inhibition effects of patchouli alcohol against influenza a virus through targeting cellular PI3K/Akt and ERK/MAPK signaling pathways. Virol J 2019;16:163. [PMID: 31870450 DOI: 10.1186/s12985-019-1266-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
3 Moreno G, Rodríguez A, Sole-Violán J, Martín-Loeches I, Díaz E, Bodí M, Reyes LF, Gómez J, Guardiola J, Trefler S, Vidaur L, Papiol E, Socias L, García-Vidal C, Correig E, Marín-Corral J, Restrepo MI, Nguyen-Van-Tam JS, Torres A. Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia. ERJ Open Res 2021;7:00888-2020. [PMID: 33718494 DOI: 10.1183/23120541.00888-2020] [Reference Citation Analysis]
4 Torres A, Chalmers JD, Dela Cruz CS, Dominedò C, Kollef M, Martin-Loeches I, Niederman M, Wunderink RG. Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med 2019;45:159-71. [PMID: 30706119 DOI: 10.1007/s00134-019-05519-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 11.3] [Reference Citation Analysis]
5 Salazar G, Zhang N, Fu TM, An Z. Antibody therapies for the prevention and treatment of viral infections. NPJ Vaccines 2017;2:19. [PMID: 29263875 DOI: 10.1038/s41541-017-0019-3] [Cited by in Crossref: 92] [Cited by in F6Publishing: 73] [Article Influence: 18.4] [Reference Citation Analysis]
6 Torres A, Loeches IM, Sligl W, Lee N. Severe flu management: a point of view. Intensive Care Med 2020;46:153-62. [PMID: 31912206 DOI: 10.1007/s00134-019-05868-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
7 Peng S, Wang J, Wei S, Li C, Zhou K, Hu J, Ye X, Yan J, Liu W, Gao GF, Fang M, Meng S. Endogenous Cellular MicroRNAs Mediate Antiviral Defense against Influenza A Virus. Mol Ther Nucleic Acids 2018;10:361-75. [PMID: 29499948 DOI: 10.1016/j.omtn.2017.12.016] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 8.4] [Reference Citation Analysis]
8 Tiwari VK, Powell DR, Broussy S, Berkowitz DB. Rapid Enantioselective and Diastereoconvergent Hybrid Organic/Biocatalytic Entry into the Oseltamivir Core. J Org Chem 2021;86:6494-503. [PMID: 33857378 DOI: 10.1021/acs.joc.1c00326] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Law N, Kumar D. Post-transplant Viral Respiratory Infections in the Older Patient: Epidemiology, Diagnosis, and Management. Drugs Aging 2017;34:743-54. [PMID: 28965331 DOI: 10.1007/s40266-017-0491-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Atto B, Eapen MS, Sharma P, Frey U, Ammit AJ, Markos J, Chia C, Larby J, Haug G, Weber HC, Mabeza G, Tristram S, Myers S, Geraghty DP, Flanagan KL, Hansbro PM, Sohal SS. New therapeutic targets for the prevention of infectious acute exacerbations of COPD: role of epithelial adhesion molecules and inflammatory pathways. Clin Sci (Lond) 2019;133:1663-703. [PMID: 31346069 DOI: 10.1042/CS20181009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
11 Martin-Loeches I, Lemiale V, Geoghegan P, McMahon MA, Pickkers P, Soares M, Perner A, Meyhoff TS, Bukan RB, Rello J, Bauer PR, van de Louw A, Taccone FS, Salluh J, Hemelaar P, Schellongowski P, Rusinova K, Terzi N, Mehta S, Antonelli M, Kouatchet A, Klepstad P, Valkonen M, Landburg PP, Barratt-Due A, Bruneel F, Pène F, Metaxa V, Moreau AS, Souppart V, Burghi G, Girault C, Silva UVA, Montini L, Barbier F, Nielsen LB, Gaborit B, Mokart D, Chevret S, Azoulay E; Efraim investigators and the Nine-I study group. Influenza and associated co-infections in critically ill immunosuppressed patients. Crit Care 2019;23:152. [PMID: 31046842 DOI: 10.1186/s13054-019-2425-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]